Article info

Download PDFPDF
Randomised controlled trial
Liraglutide, a GLP-1 receptor agonist, prevents cardiovascular outcomes in patients with type 2 diabetes

Authors

  1. Correspondence to: Dr Sheila A Doggrell, School of Biomedical Sciences, Queensland University of Technology, Brisbane, QLD 4002, Australia; sheila.doggrell{at}qut.edu.au
View Full Text

Citation

Doggrell SA
Liraglutide, a GLP-1 receptor agonist, prevents cardiovascular outcomes in patients with type 2 diabetes

Publication history

  • First published November 14, 2016.
Online issue publication 
January 24, 2017

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.